{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:58:01Z","timestamp":1792112281582,"version":"4.4.0"},"reference-count":124,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T00:00:00Z","timestamp":1596672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Postgraduate Medicine"],"published-print":{"date-parts":[[2021,1,2]]},"DOI":"10.1080\/00325481.2020.1783937","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T05:44:30Z","timestamp":1596779070000},"page":"28-41","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention"],"prefix":"10.1080","volume":"133","author":[{"given":"Kamini","family":"Trivedi","sequence":"first","affiliation":[{"name":"Independent physician, Grand Island, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6659-5332","authenticated-orcid":false,"given":"Viet","family":"Le","sequence":"additional","affiliation":[{"name":"Intermountain Medical Center, Murray, UT, USA"},{"name":"Principle PA Faculty, Rocky Mountain University of Health Professions, Provo, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2455-0296","authenticated-orcid":false,"given":"John R.","family":"Nelson","sequence":"additional","affiliation":[{"name":"California Cardiovascular Institute, Fresno, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,8,6]]},"reference":[{"issue":"10","key":"e_1_3_4_2_1","first-page":"e177","article-title":"ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"74","author":"Arnett DK","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al. ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;74(10):e177\u2013e232.","journal-title":"J Am Coll Cardiol"},{"key":"e_1_3_4_3_1","article-title":"The ABCs of primary cardiovascular prevention: 2019 update","author":"Alfaddagh A","year":"2019","unstructured":"Alfaddagh A, Arps K, Blumenthal RS, et al. The ABCs of primary cardiovascular prevention: 2019 update. J Am Coll Cardiol. 2019. [updated 2019 Mar 21, cited 2019 Mar 21]. Available from: https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2019\/03\/21\/14\/39\/abcs-of-primary-cv-prevention-2019-update-gl-prevention","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"e_1_3_4_4_1","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1016\/j.amjmed.2019.01.031","article-title":"Clinician\u2019s guide to the updated ABCs of cardiovascular disease prevention: a review part 2","volume":"132","author":"Arps K","year":"2019","unstructured":"Arps K, Pallazola VA, Cardoso R, et al. Clinician\u2019s guide to the updated ABCs of cardiovascular disease prevention: a review part 2. Am J Med. 2019;132(7):e599\u2013e609. Epub 2019\/ 02\/05.","journal-title":"Am J Med"},{"issue":"9326","key":"e_1_3_4_5_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"Heart Protection Study Collaborative Group. MRC\/BHF Heart Protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","unstructured":"Heart Protection Study Collaborative Group. MRC\/BHF Heart Protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7\u201322.","journal-title":"Lancet"},{"issue":"9435","key":"e_1_3_4_6_1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun HM","year":"2004","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685\u2013696.","journal-title":"Lancet"},{"issue":"20","key":"e_1_3_4_7_1","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas coronary atherosclerosis prevention Study","volume":"279","author":"Downs JR","year":"1998","unstructured":"Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas coronary atherosclerosis prevention Study. JAMA. 1998;279(20):1615\u20131622.","journal-title":"JAMA"},{"issue":"9364","key":"e_1_3_4_8_1","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial\u2013Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial","volume":"361","author":"Sever PS","year":"2003","unstructured":"Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial\u2013Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149\u20131158.","journal-title":"Lancet"},{"issue":"3","key":"e_1_3_4_9_1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jacc.2018.04.061","article-title":"Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management","volume":"72","author":"Ganda OP","year":"2018","unstructured":"Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330\u2013343.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"e_1_3_4_10_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt DL","year":"2019","unstructured":"Bhatt DL, Steg G, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11\u201322.","journal-title":"N Engl J Med"},{"key":"e_1_3_4_11_1","volume-title":"Living standards of medical care in diabetes","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. Living standards of medical care in diabetes. Arlington County, VA: American Diabetes Association; 2019 [updated 2019 Jul 31, cited 2019 Jul 31]. Available from: https:\/\/care.diabetesjournals.org\/living-standards#2018"},{"issue":"12","key":"e_1_3_4_12_1","first-page":"e673","article-title":"Omega-3 fatty acids for the management of hypertriglyceridemia: A science advisory from the American Heart Association","volume":"140","author":"Skulas-Ray AC","year":"2019","unstructured":"Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: A science advisory from the American Heart Association. Circulation. 2019;140(12):e673\u2013e691.","journal-title":"Circulation"},{"key":"e_1_3_4_13_1","volume-title":"National Lipid Association. NLA position on the use of icosapent ethyl in high and very-high risk patients","year":"2019","unstructured":"National Lipid Association. NLA position on the use of icosapent ethyl in high and very-high risk patients. Jacksonville, FL: National Lipid Association; 2019 [cited 2019 Sep 16]. Available from: https:\/\/www.lipid.org\/nla\/nla-position-use-icosapent-ethyl-high-and-very-high-risk-patients"},{"issue":"1","key":"e_1_3_4_14_1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach F","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111\u2013188.","journal-title":"Eur Heart J"},{"issue":"12","key":"e_1_3_4_15_1","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart disease and stroke statistics-2018 update: a report from the American Heart Association","volume":"137","author":"Benjamin EJ","year":"2018","unstructured":"Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67\u2013e492.","journal-title":"Circulation"},{"key":"e_1_3_4_16_1","unstructured":"Heart disease and stroke statistics 2018 at-a-glance: American Heart Association. American Stroke Association; 2018 [cited 2018 Feb 5]. Available from: http:\/\/professional.heart.org\/idc\/groups\/ahamah-public\/@wcm\/@sop\/@smd\/documents\/downloadable\/ucm_498848.pdf"},{"key":"e_1_3_4_17_1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jacl.2018.11.008","article-title":"Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition examination survey","volume":"13","author":"Fan W","year":"2019","unstructured":"Fan W, Philip S, Granowitz C, et al. Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition examination survey. J Clin Lipidol. 2019;13:100\u2013108.","journal-title":"J Clin Lipidol"},{"issue":"5","key":"e_1_3_4_18_1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1161\/CIRCULATIONAHA.119.044440","article-title":"REDUCE-IT USA: results from the 3,146 patients randomized in the United States","volume":"141","author":"Bhatt DL","year":"2020","unstructured":"Bhatt DL, Miller M, Brinton EA, et al. REDUCE-IT USA: results from the 3,146 patients randomized in the United States. Circulation. 2020;141(5):367\u2013375.","journal-title":"Circulation"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(19)32471-4"},{"issue":"12","key":"e_1_3_4_20_1","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1001\/jamainternmed.2016.6875","article-title":"Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis","volume":"176","author":"Pedersen SB","year":"2016","unstructured":"Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. 2016;176(12):1834\u20131842.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"e_1_3_4_21_1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/eurheartj\/ehz767","article-title":"Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies","volume":"41","author":"Lawler PR","year":"2020","unstructured":"Lawler PR, Kotrri G, Koh M, et al. Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies. Eur Heart J. 2020;41(1):86\u201394.","journal-title":"Eur Heart J"},{"issue":"7","key":"e_1_3_4_22_1","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","article-title":"Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial","volume":"51","author":"Miller M","year":"2008","unstructured":"Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51(7):724\u2013730.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"e_1_3_4_23_1","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.amjcard.2016.04.004","article-title":"Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease","volume":"118","author":"Budoff M","year":"2016","unstructured":"Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease. Am J Cardiol. 2016;118(1):138\u2013145.","journal-title":"Am J Cardiol"},{"issue":"4","key":"e_1_3_4_24_1","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard BG","year":"2016","unstructured":"Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016;118(4):547\u2013563.","journal-title":"Circ Res"},{"issue":"15","key":"e_1_3_4_25_1","doi-asserted-by":"crossref","first-page":"e008740","DOI":"10.1161\/JAHA.118.008740","article-title":"High triglycerides are associated with increased cardiovascular events, medical costs, and resource utilization: a real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk","volume":"7","author":"Toth PP","year":"2018","unstructured":"Toth PP, Granowitz C, Hull M, et al. High triglycerides are associated with increased cardiovascular events, medical costs, and resource utilization: a real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc. 2018;7(15):e008740.","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"e_1_3_4_26_1","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1080\/00325481.2017.1385365","article-title":"Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?","volume":"129","author":"Nelson JR","year":"2017","unstructured":"Nelson JR, True WS, Le V, et al. Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk? Postgrad Med. 2017;129(8):822\u2013827.","journal-title":"Postgrad Med"},{"issue":"12","key":"e_1_3_4_27_1","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1194\/jlr.R027904","article-title":"Omega-3 fatty acid supplementation and cardiovascular disease","volume":"53","author":"Jump DB","year":"2012","unstructured":"Jump DB, Depner CM, Tripathy S. Omega-3 fatty acid supplementation and cardiovascular disease. J Lipid Res. 2012;53(12):2525\u20132545.","journal-title":"J Lipid Res"},{"issue":"5","key":"e_1_3_4_28_1","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjcard.2011.04.015","article-title":"Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial)","volume":"108","author":"Bays HE","year":"2011","unstructured":"Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011;108(5):682\u2013690.","journal-title":"Am J Cardiol"},{"issue":"7","key":"e_1_3_4_29_1","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.amjcard.2012.05.031","article-title":"Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)","volume":"110","author":"Ballantyne CM","year":"2012","unstructured":"Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110(7):984\u2013992.","journal-title":"Am J Cardiol"},{"issue":"2","key":"e_1_3_4_30_1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1185\/03007995.2015.1120190","article-title":"History and future of omega-3 fatty acids in cardiovascular disease","volume":"32","author":"Sperling LS","year":"2016","unstructured":"Sperling LS, Nelson JR. History and future of omega-3 fatty acids in cardiovascular disease. Curr Med Res Opin. 2016;32(2):301\u2013311.","journal-title":"Curr Med Res Opin"},{"issue":"9567","key":"e_1_3_4_31_1","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama M","year":"2007","unstructured":"Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090\u20131098.","journal-title":"Lancet"},{"issue":"1","key":"e_1_3_4_32_1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1475-2840-12-100","article-title":"Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200\u2013500 mg\/dL), and on statin therapy at LDL-C goal: the ANCHOR study","volume":"12","author":"Brinton EA","year":"2013","unstructured":"Brinton EA, Ballantyne CM, Bays HE, et al. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200\u2013500 mg\/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovasc Diabetol. 2013;12(1):100.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"e_1_3_4_33_1","article-title":"New insights into mechanisms of action for omega-3 fatty acids in atherothrombotic cardiovascular disease","volume":"21","author":"Mason RP","year":"2019","unstructured":"Mason RP. New insights into mechanisms of action for omega-3 fatty acids in atherothrombotic cardiovascular disease. Curr Atheroscler Rep. 2019;21(2).","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"e_1_3_4_34_1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.atherosclerosis.2015.07.035","article-title":"Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis","volume":"242","author":"Borow KM","year":"2015","unstructured":"Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis. 2015;242(1):357\u2013366.","journal-title":"Atherosclerosis"},{"issue":"6","key":"e_1_3_4_35_1","first-page":"863","article-title":"Daily intake of eicosapentaenoic acid inhibits the progression of carotid intimal-media thickness in patients with dyslipidemia [in Japanese]","volume":"32","author":"Katoh A","year":"2011","unstructured":"Katoh A, Ikeda H. Daily intake of eicosapentaenoic acid inhibits the progression of carotid intimal-media thickness in patients with dyslipidemia [in Japanese]. Ther Res. 2011;32(6):863\u2013868.","journal-title":"Ther Res"},{"issue":"1","key":"e_1_3_4_36_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/clc.22856","article-title":"Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg\/dL) on statin therapy: rationale and design of the EVAPORATE study","volume":"41","author":"Budoff M","year":"2018","unstructured":"Budoff M, Brent Muhlestein J, Le VT, et al. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg\/dL) on statin therapy: rationale and design of the EVAPORATE study. Clin Cardiol. 2018;41(1):13\u201319.","journal-title":"Clin Cardiol"},{"issue":"6","key":"e_1_3_4_37_1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jjcc.2017.07.007","article-title":"A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins","volume":"70","author":"Watanabe T","year":"2017","unstructured":"Watanabe T, Ando K, Daidoji H, et al. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. J Cardiol. 2017;70(6):537\u2013544.","journal-title":"J Cardiol"},{"issue":"6","key":"e_1_3_4_38_1","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/clc.23185","article-title":"Eicosapentaenoic acid therapy is associated with decreased coronary plaque instability assessed using optical frequency domain imaging","volume":"42","author":"Konishi T","year":"2019","unstructured":"Konishi T, Sunaga D, Funayama N, et al. Eicosapentaenoic acid therapy is associated with decreased coronary plaque instability assessed using optical frequency domain imaging. Clin Cardiol. 2019;42(6):618\u2013628.","journal-title":"Clin Cardiol"},{"issue":"1","key":"e_1_3_4_39_1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.atherosclerosis.2006.03.005","article-title":"Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes","volume":"191","author":"Mita T","year":"2007","unstructured":"Mita T, Watada H, Ogihara T, et al. Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. Atherosclerosis. 2007;191(1):162\u2013167.","journal-title":"Atherosclerosis"},{"issue":"1","key":"e_1_3_4_40_1","first-page":"6","article-title":"Omega-3 products: what\u2019s inside?","volume":"2","author":"Mason RP","year":"2016","unstructured":"Mason RP, Chowdhury S. Omega-3 products: what\u2019s inside? HealthLine. 2016;2(1):6\u20137.","journal-title":"HealthLine"},{"issue":"12","key":"e_1_3_4_41_1","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1016\/j.bbamem.2016.10.002","article-title":"Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes","volume":"1858","author":"Mason RP","year":"2016","unstructured":"Mason RP, Jacob RF, Shrivastava S, et al. Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. Biochim Biophys Acta. 2016;1858(12):3131\u20133140.","journal-title":"Biochim Biophys Acta"},{"key":"e_1_3_4_42_1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.biopha.2018.04.118","article-title":"Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin","volume":"103","author":"Mason RP","year":"2018","unstructured":"Mason RP, Dawoud H, Jacob RF, et al. Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin. Biomed Pharmacother. 2018;103:1231\u20131237.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"e_1_3_4_43_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2008.06.003","article-title":"Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)","volume":"200","author":"Saito Y","year":"2008","unstructured":"Saito Y, Yokoyama M, Origasa H, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008;200(1):135\u2013140.","journal-title":"Atherosclerosis"},{"issue":"3","key":"e_1_3_4_44_1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0090-6980(79)80063-5","article-title":"Effects of all cis-5,8,11,14,17 eicosapentaenoic acid and PGH3 on platelet aggregation","volume":"18","author":"Gryglewski RJ","year":"1979","unstructured":"Gryglewski RJ, Salmon JA, Ubatuba FB, et al. Effects of all cis-5,8,11,14,17 eicosapentaenoic acid and PGH3 on platelet aggregation. Prostaglandins. 1979;18(3):453\u2013478.","journal-title":"Prostaglandins"},{"issue":"5","key":"e_1_3_4_45_1","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood.V76.5.938.938","article-title":"Fish oil: a potent inhibitor of platelet adhesiveness","volume":"76","author":"Li XL","year":"1990","unstructured":"Li XL, Steiner M. Fish oil: a potent inhibitor of platelet adhesiveness. Blood. 1990;76(5):938\u2013945.","journal-title":"Blood"},{"issue":"8","key":"e_1_3_4_46_1","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/0006-2952(96)00473-X","article-title":"Fish oil fatty acids and human platelets: dose-dependent decrease in dienoic and increase in trienoic thromboxane generation","volume":"52","author":"Kramer HJ","year":"1996","unstructured":"Kramer HJ, Stevens J, Grimminger F, et al. Fish oil fatty acids and human platelets: dose-dependent decrease in dienoic and increase in trienoic thromboxane generation. Biochem Pharmacol. 1996;52(8):1211\u20131217.","journal-title":"Biochem Pharmacol"},{"issue":"8081","key":"e_1_3_4_47_1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(78)91505-2","article-title":"Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis?","volume":"2","author":"Dyerberg J","year":"1978","unstructured":"Dyerberg J, Bang HO, Stoffersen E, et al. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet. 1978;2(8081):117\u2013119.","journal-title":"Lancet"},{"issue":"1","key":"e_1_3_4_48_1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.atherosclerosis.2014.02.025","article-title":"Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma","volume":"234","author":"Nishio R","year":"2014","unstructured":"Nishio R, Shinke T, Otake H, et al. Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma. Atherosclerosis. 2014;234(1):114\u2013119.","journal-title":"Atherosclerosis"},{"issue":"5","key":"e_1_3_4_49_1","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.amjcard.2019.05.057","article-title":"Effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) on atherogenic lipid\/lipoprotein, apolipoprotein, and inflammatory parameters in patients with elevated high-sensitivity C-reactive protein (from the ANCHOR study)","volume":"124","author":"Miller M","year":"2019","unstructured":"Miller M, Ballantyne CM, Bays HE, et al. Effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) on atherogenic lipid\/lipoprotein, apolipoprotein, and inflammatory parameters in patients with elevated high-sensitivity C-reactive protein (from the ANCHOR study). Am J Cardiol. 2019;124(5):696\u2013701.","journal-title":"Am J Cardiol"},{"key":"e_1_3_4_50_1","doi-asserted-by":"crossref","first-page":"117133","DOI":"10.1016\/j.lfs.2019.117133","article-title":"Eicosapentaenoic acid prevents inflammation induced by acute cerebral infarction through inhibition of NLRP3 inflammasome activation","volume":"242","author":"Mo Z","year":"2020","unstructured":"Mo Z, Tang C, Li H, et al. Eicosapentaenoic acid prevents inflammation induced by acute cerebral infarction through inhibition of NLRP3 inflammasome activation. Life Sci. 2020;242:117133.","journal-title":"Life Sci"},{"issue":"3","key":"e_1_3_4_51_1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1210\/js.2018-00220","article-title":"Fish oil derived omega 3 fatty acids suppress adipose NLRP3 inflammasome signaling in human obesity","volume":"3","author":"Lee KR","year":"2019","unstructured":"Lee KR, Midgette Y, Shah R. Fish oil derived omega 3 fatty acids suppress adipose NLRP3 inflammasome signaling in human obesity. J Endocr Soc. 2019;3(3):504\u2013515.","journal-title":"J Endocr Soc"},{"issue":"3","key":"e_1_3_4_52_1","doi-asserted-by":"crossref","DOI":"10.3390\/nu11030599","article-title":"Eicosapentaenoic acid improves hepatic metabolism and reduces inflammation independent of obesity in high-fat-fed mice and in HepG2 cells","volume":"11","author":"Albracht-Schulte K","year":"2019","unstructured":"Albracht-Schulte K, Gonzalez S, Jackson A, et al. Eicosapentaenoic acid improves hepatic metabolism and reduces inflammation independent of obesity in high-fat-fed mice and in HepG2 cells. Nutrients. 2019;11(3):599.","journal-title":"Nutrients"},{"key":"e_1_3_4_53_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12944-016-0241-4","article-title":"Effect of n-3 fatty acids on the expression of inflammatory genes in THP-1 macrophages","volume":"15","author":"Allam-Ndoul B","year":"2016","unstructured":"Allam-Ndoul B, Guenard F, Barbier O, et al. Effect of n-3 fatty acids on the expression of inflammatory genes in THP-1 macrophages. Lipids Health Dis. 2016;15:69.","journal-title":"Lipids Health Dis"},{"issue":"1","key":"e_1_3_4_54_1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.plefa.2008.07.002","article-title":"Eicosapentaenoic acid inhibits interleukin-6 production in interleukin-1beta-stimulated C6 glioma cells through peroxisome proliferator-activated receptor-gamma","volume":"79","author":"Kawashima A","year":"2008","unstructured":"Kawashima A, Harada T, Imada K, et al. Eicosapentaenoic acid inhibits interleukin-6 production in interleukin-1beta-stimulated C6 glioma cells through peroxisome proliferator-activated receptor-gamma. Prostaglandins Leukot Essent Fatty Acids. 2008;79(1\u20132):59\u201365.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"4","key":"e_1_3_4_55_1","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1194\/jlr.P031260","article-title":"Evaluation of suppressive and pro-resolving effects of EPA and DHA in human primary monocytes and T-helper cells","volume":"54","author":"Jaudszus A","year":"2013","unstructured":"Jaudszus A, Gruen M, Watzl B, et al. Evaluation of suppressive and pro-resolving effects of EPA and DHA in human primary monocytes and T-helper cells. J Lipid Res. 2013;54(4):923\u2013935.","journal-title":"J Lipid Res"},{"issue":"12","key":"e_1_3_4_56_1","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.2337\/dc12-0269","article-title":"Highly purified eicosapentaenoic acid increases interleukin-10 levels of peripheral blood monocytes in obese patients with dyslipidemia","volume":"35","author":"Satoh-Asahara N","year":"2012","unstructured":"Satoh-Asahara N, Shimatsu A, Sasaki Y, et al. Highly purified eicosapentaenoic acid increases interleukin-10 levels of peripheral blood monocytes in obese patients with dyslipidemia. Diabetes Care. 2012;35(12):2631\u20132639.","journal-title":"Diabetes Care"},{"issue":"12","key":"e_1_3_4_57_1","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1161\/ATVBAHA.108.171736","article-title":"In vivo and in vitro inhibition of monocyte adhesion to endothelial cells and endothelial adhesion molecules by eicosapentaenoic acid","volume":"28","author":"Yamada H","year":"2008","unstructured":"Yamada H, Yoshida M, Nakano Y, et al. In vivo and in vitro inhibition of monocyte adhesion to endothelial cells and endothelial adhesion molecules by eicosapentaenoic acid. Arterioscler Thromb Vasc Biol. 2008;28(12):2173\u20132179.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"e_1_3_4_58_1","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.4049\/jimmunol.178.6.3912","article-title":"Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation","volume":"178","author":"Arita M","year":"2007","unstructured":"Arita M, Ohira T, Sun YP, et al. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol. 2007;178(6):3912\u20133917.","journal-title":"J Immunol"},{"issue":"9","key":"e_1_3_4_59_1","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.4049\/jimmunol.1103652","article-title":"Resolvin E2 formation and impact in inflammation resolution","volume":"188","author":"Oh SF","year":"2012","unstructured":"Oh SF, Dona M, Fredman G, et al. Resolvin E2 formation and impact in inflammation resolution. J Immunol. 2012;188(9):4527\u20134534.","journal-title":"J Immunol"},{"issue":"13","key":"e_1_3_4_60_1","doi-asserted-by":"crossref","first-page":"10525","DOI":"10.1074\/jbc.M112.340612","article-title":"Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid","volume":"287","author":"Isobe Y","year":"2012","unstructured":"Isobe Y, Arita M, Matsueda S, et al. Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid. J Biol Chem. 2012;287(13):10525\u201310534.","journal-title":"J Biol Chem"},{"issue":"8","key":"e_1_3_4_61_1","first-page":"486","article-title":"The effect of eicosapentaenoic acid on the serum levels and enzymatic activity of paraoxonase 1 in the patients with type 2 diabetes mellitus","volume":"55","author":"Golzari MH","year":"2017","unstructured":"Golzari MH, Hosseini S, Koohdani F, et al. The effect of eicosapentaenoic acid on the serum levels and enzymatic activity of paraoxonase 1 in the patients with type 2 diabetes mellitus. Acta Med Iran. 2017;55(8):486\u2013495.","journal-title":"Acta Med Iran"},{"issue":"1","key":"e_1_3_4_62_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7762\/cnr.2019.8.1.17","article-title":"Effect of eicosapentaenoic acid supplementation on paraoxonase 2 gene expression in patients with type 2 diabetes mellitus: a randomized double-blind clinical trial","volume":"8","author":"Golzari MH","year":"2019","unstructured":"Golzari MH, Javanbakht MH, Ghaedi E, et al. Effect of eicosapentaenoic acid supplementation on paraoxonase 2 gene expression in patients with type 2 diabetes mellitus: a randomized double-blind clinical trial. Clin Nutr Res. 2019;8(1):17\u201327.","journal-title":"Clin Nutr Res"},{"key":"e_1_3_4_63_1","article-title":"Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro","volume":"1862","author":"Sherratt SCR","year":"2020","unstructured":"Sherratt SCR, Juliano RA, Mason RP. Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro. Biochimica Et Biophysica Acta Biomembranes. 2020;1862:183254. Epub ahead of print.","journal-title":"Biochimica Et Biophysica Acta Biomembranes"},{"issue":"2","key":"e_1_3_4_64_1","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1006\/bbrc.1997.6328","article-title":"Eicosapentaenoic acid enhances nitric oxide production by cultured human endothelial cells","volume":"232","author":"Okuda Y","year":"1997","unstructured":"Okuda Y, Kawashima K, Sawada T, et al. Eicosapentaenoic acid enhances nitric oxide production by cultured human endothelial cells. Biochem Biophys Res Commun. 1997;232(2):487\u2013491.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"e_1_3_4_65_1","first-page":"3816","article-title":"Increase in EPA\/AA ratio predicts improvement in endothelial function in purified eicosapentaenoic acid-treated patients [abstract P6205]","volume":"40","author":"Fukumoto K","year":"2019","unstructured":"Fukumoto K, Takemoto Y, Yoshikawa J, et al. Increase in EPA\/AA ratio predicts improvement in endothelial function in purified eicosapentaenoic acid-treated patients [abstract P6205]. Eur Heart J. 2019;40(suppl 1):3816.","journal-title":"Eur Heart J"},{"key":"e_1_3_4_66_1","doi-asserted-by":"crossref","first-page":"754181","DOI":"10.1155\/2012\/754181","article-title":"Eicosapentaenoic acid supplementation changes fatty acid composition and corrects endothelial dysfunction in hyperlipidemic patients","volume":"2012","author":"Yamakawa K","year":"2012","unstructured":"Yamakawa K, Shimabukuro M, Higa N, et al. Eicosapentaenoic acid supplementation changes fatty acid composition and corrects endothelial dysfunction in hyperlipidemic patients. Cardiol Res Pract. 2012;2012:754181.","journal-title":"Cardiol Res Pract"},{"issue":"4","key":"e_1_3_4_67_1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1507\/endocrj.EJ11-0394","article-title":"Administration of highly purified eicosapentaenoic acid to statin-treated diabetic patients further improves vascular function","volume":"59","author":"Sasaki J","year":"2012","unstructured":"Sasaki J, Miwa T, Odawara M. Administration of highly purified eicosapentaenoic acid to statin-treated diabetic patients further improves vascular function. Endocr J. 2012;59(4):297\u2013304.","journal-title":"Endocr J"},{"issue":"1","key":"e_1_3_4_68_1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10557-013-6496-3","article-title":"Eicosapentaenoic acid combined with optimal statin therapy improves endothelial dysfunction in patients with coronary artery disease","volume":"28","author":"Toyama K","year":"2014","unstructured":"Toyama K, Nishioka T, Isshiki A, et al. Eicosapentaenoic acid combined with optimal statin therapy improves endothelial dysfunction in patients with coronary artery disease. Cardiovasc Drugs Ther. 2014;28(1):53\u201359.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"e_1_3_4_69_1","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1253\/circj.CJ-17-0294","article-title":"Eicosapentaenoic acid-enriched high-density lipoproteins exhibit anti-atherogenic properties","volume":"82","author":"Tanaka N","year":"2018","unstructured":"Tanaka N, Irino Y, Shinohara M, et al. Eicosapentaenoic acid-enriched high-density lipoproteins exhibit anti-atherogenic properties. Circ J. 2018;82(2):596\u2013601.","journal-title":"Circ J"},{"issue":"9","key":"e_1_3_4_70_1","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1161\/ATVBAHA.106.136853","article-title":"Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects","volume":"27","author":"Itoh M","year":"2007","unstructured":"Itoh M, Suganami T, Satoh N, et al. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol. 2007;27(9):1918\u20131925.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"e_1_3_4_71_1","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1073\/pnas.94.8.4182","article-title":"Suppression of voltage-gated L-type Ca2+ currents by polyunsaturated fatty acids in adult and neonatal rat ventricular myocytes","volume":"94","author":"Xiao YF","year":"1997","unstructured":"Xiao YF, Gomez AM, Morgan JP, et al. Suppression of voltage-gated L-type Ca2+ currents by polyunsaturated fatty acids in adult and neonatal rat ventricular myocytes. Proc Natl Acad Sci USA. 1997;94(8):4182\u20134187.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"e_1_3_4_72_1","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1073\/pnas.061003798","article-title":"Single point mutations affect fatty acid block of human myocardial sodium channel alpha subunit Na+ channels","volume":"98","author":"Xiao YF","year":"2001","unstructured":"Xiao YF, Ke Q, Wang SY, et al. Single point mutations affect fatty acid block of human myocardial sodium channel alpha subunit Na+ channels. Proc Natl Acad Sci USA. 2001;98(6):3606\u20133611.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_73_1","volume-title":"Reduction of cardiovascular events with icosapent ethyl\u2013intervention trial [oral presentation]","author":"Bhatt DL","year":"2018","unstructured":"Bhatt DL, Steg G, Miller M, et al. Reduction of cardiovascular events with icosapent ethyl\u2013intervention trial [oral presentation]. Chicago (IL); 2018 Nov 10\u201312."},{"key":"e_1_3_4_74_1","article-title":"Effects of icosapent ethyl on total ischemic events: from REDUCE-IT","author":"Bhatt DL","year":"2019","unstructured":"Bhatt DL, Steg G, Miller M, et al. Effects of icosapent ethyl on total ischemic events: from REDUCE-IT. J Am Coll Cardiol. 2019;380:2791\u20132802.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"e_1_3_4_75_1","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","article-title":"Effects of icosapent ethyl on total ischemic events: from REDUCE-IT","volume":"73","author":"Bhatt DL","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, et al. Effects of icosapent ethyl on total ischemic events: from REDUCE-IT. J Am Coll Cardiol. 2019;73(22):2791\u20132802.","journal-title":"J Am Coll Cardiol"},{"key":"e_1_3_4_76_1","volume-title":"EPA levels and cardiovascular outcomes in the reduction of cardiovascular events with icosapent ethyl-intervention trial [oral presentation]","author":"Bhatt DL","year":"2020","unstructured":"Bhatt DL, Miller M, Steg G, et al. EPA levels and cardiovascular outcomes in the reduction of cardiovascular events with icosapent ethyl-intervention trial [oral presentation]. Chicago (IL); 2020 Mar 28-30;380:2791\u20132802."},{"issue":"1","key":"e_1_3_4_77_1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMe1814004","article-title":"FISHing for the miracle of eicosapentaenoic acid","volume":"380","author":"Kastelein JJP","year":"2019","unstructured":"Kastelein JJP, Stroes ESG. FISHing for the miracle of eicosapentaenoic acid. N Engl J Med. 2019;380(1):89\u201390.","journal-title":"N Engl J Med"},{"key":"e_1_3_4_78_1","volume-title":"Vascepa [package insert]","year":"2019","unstructured":"Vascepa [package insert]. Bridgewater (NJ): Amarin Pharma Inc.; 2019."},{"key":"e_1_3_4_79_1","doi-asserted-by":"crossref","DOI":"10.1161\/ATVBAHA.119.313286","article-title":"Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid","volume":"40","author":"Mason RP","year":"2020","unstructured":"Mason RP, Libby P, Bhatt DL. Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid. Arterioscler Thromb Vasc Biol. 2020;40:1135\u20131147. Epub ahead of print.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"14","key":"e_1_3_4_80_1","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker PM","year":"1997","unstructured":"Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336(14):973\u2013979.","journal-title":"N Engl J Med"},{"issue":"12","key":"e_1_3_4_81_1","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker PM","year":"2000","unstructured":"Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836\u2013843.","journal-title":"N Engl J Med"},{"issue":"14","key":"e_1_3_4_82_1","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1056\/NEJMoa032804","article-title":"C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease","volume":"350","author":"Danesh J","year":"2004","unstructured":"Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350(14):1387\u20131397.","journal-title":"N Engl J Med"},{"issue":"7255","key":"e_1_3_4_83_1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/bmj.321.7255.199","article-title":"Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses","volume":"321","author":"Danesh J","year":"2000","unstructured":"Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321(7255):199\u2013204.","journal-title":"BMJ"},{"issue":"2","key":"e_1_3_4_84_1","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ejvs.2017.05.009","article-title":"Systematic review and meta-analysis of the association between c-reactive protein and major cardiovascular events in patients with peripheral artery disease","volume":"54","author":"Singh TP","year":"2017","unstructured":"Singh TP, Morris DR, Smith S, et al. Systematic review and meta-analysis of the association between c-reactive protein and major cardiovascular events in patients with peripheral artery disease. Eur J Vasc Endovasc Surg. 2017;54(2):220\u2013233.","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"12","key":"e_1_3_4_85_1","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker PM","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119\u20131131.","journal-title":"N Engl J Med"},{"issue":"10118","key":"e_1_3_4_86_1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker PM","year":"2018","unstructured":"Ridker PM, MacFadyen JG, Everett BM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319\u2013328.","journal-title":"Lancet"},{"issue":"17","key":"e_1_3_4_87_1","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1001\/jama.1995.03530170043030","article-title":"Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest","volume":"274","author":"Siscovick DS","year":"1995","unstructured":"Siscovick DS, Raghunathan TE, King I, et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA. 1995;274(17):1363\u20131367.","journal-title":"JAMA"},{"issue":"15","key":"e_1_3_4_88_1","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa012918","article-title":"Blood levels of long-chain n-3 fatty acids and the risk of sudden death","volume":"346","author":"Albert CM","year":"2002","unstructured":"Albert CM, Campos H, Stampfer MJ, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med. 2002;346(15):1113\u20131118.","journal-title":"N Engl J Med"},{"issue":"6","key":"e_1_3_4_89_1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00380-013-0435-x","article-title":"Low serum eicosapentaenoic acid level is a risk for ventricular arrhythmia in patients with acute myocardial infarction: a possible link to J-waves","volume":"29","author":"Endo T","year":"2014","unstructured":"Endo T, Tomita H, Higuma T, et al. Low serum eicosapentaenoic acid level is a risk for ventricular arrhythmia in patients with acute myocardial infarction: a possible link to J-waves. Heart Vessels. 2014;29(6):847\u2013854.","journal-title":"Heart Vessels"},{"issue":"5","key":"e_1_3_4_90_1","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1536\/ihj.16-278","article-title":"Low serum levels of eicosapentaenoic acid and docosahexaenoic acid are risk factors for cardiogenic syncope in patients with Brugada syndrome","volume":"58","author":"Yagi S","year":"2017","unstructured":"Yagi S, Soeki T, Aihara KI, et al. Low serum levels of eicosapentaenoic acid and docosahexaenoic acid are risk factors for cardiogenic syncope in patients with Brugada syndrome. Int Heart J. 2017;58(5):720\u2013723.","journal-title":"Int Heart J"},{"key":"e_1_3_4_91_1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ijcard.2014.08.055","article-title":"Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: a randomized, controlled study","volume":"176","author":"Doi M","year":"2014","unstructured":"Doi M, Nosaka K, Miyoshi T, et al. Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: a randomized, controlled study. Int J Cardiol. 2014;176:577\u2013582.","journal-title":"Int J Cardiol"},{"issue":"16","key":"e_1_3_4_92_1","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1161\/01.CIR.0000014682.14181.F2","article-title":"Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell\u2019Infarto Miocardico (GISSI)-Prevenzione","volume":"105","author":"Marchioli R","year":"2002","unstructured":"Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell\u2019Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002;105(16):1897\u20131903.","journal-title":"Circulation"},{"issue":"4","key":"e_1_3_4_93_1","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1161\/CIRCULATIONAHA.107.733329","article-title":"Acute administration of fish oil inhibits triggered activity in isolated myocytes from rabbits and patients with heart failure","volume":"117","author":"Den Ruijter HM","year":"2008","unstructured":"Den Ruijter HM, Berecki G, Verkerk AO, et al. Acute administration of fish oil inhibits triggered activity in isolated myocytes from rabbits and patients with heart failure. Circulation. 2008;117(4):536\u2013544.","journal-title":"Circulation"},{"key":"e_1_3_4_94_1","doi-asserted-by":"crossref","first-page":"D98","DOI":"10.1016\/S1520-765X(01)90127-0","article-title":"The electrophysiological basis for the antiarrhythmic actions of polyunsaturated fatty acids","volume":"3","author":"Leaf A","year":"2001","unstructured":"Leaf A. The electrophysiological basis for the antiarrhythmic actions of polyunsaturated fatty acids. Eur Heart J Suppl. 2001;3(supplD):D98\u2013D105.","journal-title":"Eur Heart J Suppl"},{"issue":"2","key":"e_1_3_4_95_1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5551\/jat.5876","article-title":"Relationships between plasma fatty acid composition and coronary artery disease","volume":"18","author":"Itakura H","year":"2011","unstructured":"Itakura H, Yokoyama M, Matsuzaki M, et al. Relationships between plasma fatty acid composition and coronary artery disease. J Atheroscler Thromb. 2011;18(2):99\u2013107.","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"e_1_3_4_96_1","first-page":"12","article-title":"Eicosapentaenoic acid: pleiotrope extraordinaire?","volume":"15","author":"Le V","year":"2017","unstructured":"Le V, Nelson JR. Eicosapentaenoic acid: pleiotrope extraordinaire? LipidSpin. 2017;15(1):12\u201314 35.","journal-title":"LipidSpin"},{"issue":"10","key":"e_1_3_4_97_1","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/13696998.2016.1207652","article-title":"A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United States","volume":"19","author":"Philip S","year":"2016","unstructured":"Philip S, Chowdhury S, Nelson JR, et al. A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United States. J Med Econ. 2016;19(10):1003\u20131010.","journal-title":"J Med Econ"},{"key":"e_1_3_4_98_1","unstructured":"Ollendorf D McQueen R Fazioli K et al. Additive therapies for cardiovascular disease: effectiveness and value. Institute for Clinical and Economic Review; 2019 Nov 11 [cited 2020 Jun 25]. Available from: https:\/\/icer-review.org\/material\/cvd-final-evidence-report\/"},{"issue":"22","key":"e_1_3_4_99_1","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1161\/CIR.0000000000000042","article-title":"ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association task force on performance measures and task force on practice guidelines","volume":"129","author":"Anderson JL","year":"2014","unstructured":"Anderson JL, Heidenreich PA, Barnett PG, et al. ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association task force on performance measures and task force on practice guidelines. Circulation. 2014;129(22):2329\u20132345.","journal-title":"Circulation"},{"key":"e_1_3_4_100_1","volume-title":"Cost-effectiveness of icosapent ethyl in REDUCE-IT [abstract]","author":"Weintraub WS","year":"2019","unstructured":"Weintraub WS, Bhatt DL, Zhang Z, et al. Cost-effectiveness of icosapent ethyl in REDUCE-IT [abstract]. Presentation at the American Heart Association meeting. Philadelphia (PA); 2019 Nov 16\u201318."},{"issue":"1","key":"e_1_3_4_101_1","first-page":"S1","article-title":"Standards of medical care in diabetes - 2019","volume":"41","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. Standards of medical care in diabetes - 2019. Diabetes Care. 2019;41(suppl 1):S1\u2013S193.","journal-title":"Diabetes Care"},{"issue":"19","key":"e_1_3_4_102_1","doi-asserted-by":"crossref","first-page":"e779","DOI":"10.1161\/CIR.0000000000000766","article-title":"Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association","volume":"141","author":"Arnold SV","year":"2020","unstructured":"Arnold SV, Bhatt DL, Barsness GW, et al. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 2020;141(19):e779\u2013e806.","journal-title":"Circulation"},{"issue":"1","key":"e_1_3_4_103_1","first-page":"S111","article-title":"Cardiovascular disease and risk management: standards of medical care in diabetes-2020","volume":"43","year":"2020","unstructured":"Cardiovascular disease and risk management: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S111\u2013s134.","journal-title":"Diabetes Care"},{"issue":"24","key":"e_1_3_4_104_1","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart association task force on clinical practice guidelines","volume":"73","author":"Grundy SM","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):e285\u2013e350.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"e_1_3_4_105_1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.4158\/EP171764.GL","article-title":"American association of clinical endocrinologists and American college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease: executive summary","volume":"23","author":"Jellinger PS","year":"2017","unstructured":"Jellinger PS, Handelsman Y, Rosenblit PD, et al. American association of clinical endocrinologists and American college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease: executive summary. Endocr Pract. 2017;23(4):479\u2013497.","journal-title":"Endocr Pract"},{"issue":"4","key":"e_1_3_4_106_1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/clc.22713","article-title":"PCSK9 inhibitor access barriers-issues and recommendations: improving the access process for patients, clinicians and payers","volume":"40","author":"Baum SJ","year":"2017","unstructured":"Baum SJ, Toth PP, Underberg JA, et al. PCSK9 inhibitor access barriers-issues and recommendations: improving the access process for patients, clinicians and payers. Clin Cardiol. 2017;40(4):243\u2013254.","journal-title":"Clin Cardiol"},{"issue":"1","key":"e_1_3_4_107_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","article-title":"Statin intolerance - an attempt at a unified definition. Position paper from an international lipid expert panel","volume":"11","author":"Banach M","year":"2015","unstructured":"Banach M, Rizzo M, Toth PP, et al. Statin intolerance - an attempt at a unified definition. Position paper from an international lipid expert panel. Arch Med Sci. 2015;11(1):1\u201323.","journal-title":"Arch Med Sci"},{"issue":"1","key":"e_1_3_4_108_1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","article-title":"2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology task force on clinical expert consensus documents","volume":"68","author":"Lloyd-Jones DM","year":"2016","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology task force on clinical expert consensus documents. J Am Coll Cardiol. 2016;68(1):92\u2013125.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"e_1_3_4_109_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1811403","article-title":"Marine n-3 fatty acids and prevention of cardiovascular disease and cancer","volume":"380","author":"Manson JE","year":"2019","unstructured":"Manson JE, Cook NR, Lee IM, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019;380(1):23\u201332.","journal-title":"N Engl J Med"},{"issue":"16","key":"e_1_3_4_110_1","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n-3 fatty acid supplements in diabetes mellitus","volume":"379","author":"Bowman L","year":"2018","unstructured":"ASCEND Study Collaborative Group, Bowman L, Mafham M, et al. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;379(16):1540\u20131550.","journal-title":"N Engl J Med"},{"issue":"16","key":"e_1_3_4_111_1","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1161\/CIRCULATIONAHA.119.041998","article-title":"Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: A systematic review and meta-regression analysis of randomized controlled trials","volume":"140","author":"Marston NA","year":"2019","unstructured":"Marston NA, Giugliano RP, Im K, et al. Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: A systematic review and meta-regression analysis of randomized controlled trials. Circulation. 2019;140(16):1308\u20131317.","journal-title":"Circulation"},{"issue":"2","key":"e_1_3_4_112_1","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/MOL.0000000000000665","article-title":"Are dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence","volume":"31","author":"Sherratt SCR","year":"2020","unstructured":"Sherratt SCR, Lero M, Mason RP. Are dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence. Curr Opin Lipidol. 2020;31(2):94\u2013100.","journal-title":"Curr Opin Lipidol"},{"key":"e_1_3_4_113_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2017.02.004","article-title":"Potential benefits of eicosapentaenoic acid on atherosclerotic plaques","volume":"91","author":"Nelson JR","year":"2017","unstructured":"Nelson JR, Wani O, May HT, et al. Potential benefits of eicosapentaenoic acid on atherosclerotic plaques. Vascul Pharmacol. 2017;91:1\u20139.","journal-title":"Vascul Pharmacol"},{"issue":"9","key":"e_1_3_4_114_1","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1161\/ATVBAHA.119.313093","article-title":"Preferential incorporation of administered eicosapentaenoic acid into thin-cap atherosclerotic plaques","volume":"39","author":"Sato T","year":"2019","unstructured":"Sato T, Horikawa M, Takei S, et al. Preferential incorporation of administered eicosapentaenoic acid into thin-cap atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2019;39(9):1802\u20131816.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"e_1_3_4_115_1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbrc.2018.01.062","article-title":"Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid","volume":"496","author":"Sherratt SCR","year":"2018","unstructured":"Sherratt SCR, Mason RP. Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid. Biochem Biophys Res Commun. 2018;496(2):335\u2013338.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"e_1_3_4_116_1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/FJC.0000000000000379","article-title":"Eicosapentaenoic acid inhibits oxidation of apoB-containing lipoprotein particles of different size in vitro when administered alone or in combination with atorvastatin active metabolite compared with other triglyceride-lowering agents","volume":"68","author":"Mason RP","year":"2016","unstructured":"Mason RP, Sherratt SCR, Jacob RF. Eicosapentaenoic acid inhibits oxidation of apoB-containing lipoprotein particles of different size in vitro when administered alone or in combination with atorvastatin active metabolite compared with other triglyceride-lowering agents. J Cardiovasc Pharmacol. 2016;68(1):33\u201340.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"e_1_3_4_117_1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.bbrc.2016.12.127","article-title":"Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits","volume":"483","author":"Mason RP","year":"2017","unstructured":"Mason RP, Sherratt SCR. Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits. Biochem Biophys Res Commun. 2017;483(1):425\u2013429.","journal-title":"Biochem Biophys Res Commun"},{"issue":"24","key":"e_1_3_4_118_1","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden WE","year":"2011","unstructured":"The AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255\u20132267.","journal-title":"N Engl J Med"},{"issue":"3","key":"e_1_3_4_119_1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"The HPS2-THRIVE Collaborative Group","year":"2014","unstructured":"The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203\u2013212.","journal-title":"N Engl J Med"},{"issue":"17","key":"e_1_3_4_120_1","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg HN","year":"2010","unstructured":"The ACCORD Study Group, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563\u20131574.","journal-title":"N Engl J Med"},{"issue":"9500","key":"e_1_3_4_121_1","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech A","year":"2005","unstructured":"The FIELD Study Investigators, Keech A, Simes RJ, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849\u20131861.","journal-title":"Lancet"},{"issue":"8","key":"e_1_3_4_122_1","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1185\/03007995.2010.489341","article-title":"Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i)","volume":"26","author":"Fruchart JC","year":"2010","unstructured":"Fruchart JC, Sacks FM, Hermans MP. Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i). Curr Med Res Opin. 2010;26(8):1793\u20131797.","journal-title":"Curr Med Res Opin"},{"key":"e_1_3_4_123_1","unstructured":"Randomized trial for evaluation in secondary prevention efficacy of combination therapy - statin and eicosapentaenoic acid UMIN000012069. UMIN Clinical Trials Registry; 2016 [updated 2017 Jan 9]. Available from: https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr\/ctr.cgi?function=brows&action=brows&recptno=R000014051&type=summary&language=E"},{"issue":"10","key":"e_1_3_4_124_1","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/clc.23055","article-title":"Assessment of omega-3 carboxylic acids in statin treated patients with high levels of triglycerides and low levels of high density lipoprotein cholesterol: rationale and design of the STRENGTH trial","volume":"41","author":"Nicholls SJ","year":"2018","unstructured":"Nicholls SJ, Lincoff AM, Bash D, et al. Assessment of omega-3 carboxylic acids in statin treated patients with high levels of triglycerides and low levels of high density lipoprotein cholesterol: rationale and design of the STRENGTH trial. Clin Cardiol. 2018;41(10):1281\u20131288.","journal-title":"Clin Cardiol"},{"key":"e_1_3_4_125_1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1471-2318-14-74","article-title":"Effects of omega3 supplementation in elderly patients with acute myocardial infarction: design of a prospective randomized placebo controlled study","volume":"14","author":"Laake K","year":"2014","unstructured":"Laake K, Myhre P, Nordby LM, et al. Effects of omega3 supplementation in elderly patients with acute myocardial infarction: design of a prospective randomized placebo controlled study. BMC Geriatr. 2014;14:74.","journal-title":"BMC Geriatr"}],"updated-by":[{"DOI":"10.1080\/00325481.2023.2265221","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000}}],"container-title":["Postgraduate Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/00325481.2020.1783937","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T13:48:18Z","timestamp":1696513698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/00325481.2020.1783937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,6]]},"references-count":124,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,2]]}},"alternative-id":["10.1080\/00325481.2020.1783937"],"URL":"https:\/\/doi.org\/10.1080\/00325481.2020.1783937","relation":{"correction":[{"id-type":"doi","id":"10.1080\/00325481.2023.2265221","asserted-by":"object"}]},"ISSN":["0032-5481","1941-9260"],"issn-type":[{"value":"0032-5481","type":"print"},{"value":"1941-9260","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-01-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}